Keryx Biopharmaceuticals (NASDAQ:KERX)’s share price shot up 5% during mid-day trading on Friday . The stock traded as high as $2.96 and last traded at $2.94. 987,719 shares changed hands during trading, a decline of 10% from the average session volume of 1,095,031 shares. The stock had previously closed at $2.80.
Several brokerages recently issued reports on KERX. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. HC Wainwright set a $9.00 price target on shares of Keryx Biopharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 2nd. BidaskClub upgraded shares of Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 21st. Finally, Citigroup reduced their price target on shares of Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.25.
The stock has a market cap of $345.48 million, a PE ratio of -3.34 and a beta of 2.44.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The company had revenue of $25.75 million for the quarter. On average, research analysts forecast that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in shares of Keryx Biopharmaceuticals by 10.7% during the second quarter. Bank of New York Mellon Corp now owns 1,056,811 shares of the biopharmaceutical company’s stock valued at $3,974,000 after buying an additional 102,014 shares during the period. Rice Hall James & Associates LLC increased its position in shares of Keryx Biopharmaceuticals by 18.9% during the second quarter. Rice Hall James & Associates LLC now owns 2,278,007 shares of the biopharmaceutical company’s stock valued at $8,565,000 after buying an additional 361,533 shares during the period. UBS Group AG grew its holdings in Keryx Biopharmaceuticals by 126.0% in the first quarter. UBS Group AG now owns 231,934 shares of the biopharmaceutical company’s stock worth $949,000 after purchasing an additional 129,296 shares during the period. BlackRock Inc. grew its holdings in Keryx Biopharmaceuticals by 8.8% in the second quarter. BlackRock Inc. now owns 6,613,445 shares of the biopharmaceutical company’s stock worth $24,866,000 after purchasing an additional 534,831 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Keryx Biopharmaceuticals in the second quarter worth about $399,000. Institutional investors own 59.52% of the company’s stock.
Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Recommended Story: What are retained earnings?
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.